FDA Approves LIDOCAINE — Fresenius Kabi USA, LLC

The FDA has approved a submission involving LIDOCAINE HYDROCHLORIDE (INN) for intravenous use by Fresenius Kabi USA, LLC, reinforcing the company's existing portfolio of injectable anesthetics and potentially strengthening its market position against competitors. This regulatory action validates the specific formulation, allowing Fresenius Kabi to meet growing hospital demand for reliable anesthetic solutions amidst ongoing supply chain constraints.